Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention
Executive Summary
UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.
You may also be interested in...
Novo Nordisk's Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed
A 30-day supply of the first oral GLP-1 agonist will cost $772.43 in the US, similar to the injectable version but steeper than oral diabetes medicines. Deep discounts may be needed to secure market access.
OptumRx WatchList Includes Rare Disease Drugs, Potential Price Disruptors
Pharmacy benefit manager’s new pipeline report offers insight into upcoming drugs of concern to payers.
Bluebird Lays Some New Eggs, But They'll Take Time To Hatch
Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.